PROCOS

PROCOS S.p.A., founded in Italy in 1945 and now wholly owned by the Japanese conglomerate CBC Co. Ltd Group since its acquisition in 2006, specializes as a leading contract development and manufacturing organization focused on Active Pharmaceutical Ingredients (APIs), highly potent APIs (HPAPIs), advanced intermediates—including linker-payload components for antibody-drug conjugates—and peptide-based drugs ("tides"). The company's multipurpose cGMP facility near Novara features extensive reactor capacity (>560 m³) across five buildings supporting R&D through full-scale commercial production under strict regulatory oversight from global authorities such as the FDA/AIFA/PMDA/EMA. PROCOS serves more than seventy countries globally—with strong business presence especially in the US market—and provides end-to-end support spanning preclinical research material through large-scale generic or custom API manufacture, including specialized capabilities for high-potency compounds required by modern oncology therapeutics like ADC drug-linkers. The company does not develop proprietary drugs or maintain an internal pipeline but instead enables pharmaceutical innovators worldwide via advanced chemical synthesis technologies such as flow chemistry/QbD/process automation while maintaining robust quality systems validated by regular international inspections.